...

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Biomarkers to distinguish hazardous from harmless ductal carcinoma in situ (DCIS) of the breast

【24h】

Biomarkers to distinguish hazardous from harmless ductal carcinoma in situ (DCIS) of the breast

机译：生物标志物可区分乳腺危险与无害原位导管癌（DCIS）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第2期|共1页
作者
Visser L.; Elshof L.; de Vijver K. Van; Groen E.; Nieboer F.; Maaker M.; Schaapverld M.; Rutgers E.; Lips E.; Wesseling J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Biomarkers to distinguish hazardous from harmless ductal carcinoma in situ (DCIS) of the breast [J] . Visser L., Elshof L., de Vijver K. Van, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Suppla2期

机译：生物标志物可区分乳腺危险与无害原位导管癌（DCIS）
2. Expression of cytokeratin markers, ER-alpha, PR, HER-2eu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. [J] . Steinman S, Wang J, Bourne P, Annals of Clinical and Laboratory Science: Official Journal of the Association of Clinical Scientists . 2007,第2期

机译：细胞角蛋白标志物，ER-alpha，PR，HER-2 / neu和EGFR在乳腺原位导管癌（DCIS）和DCIS与并存的浸润性导管癌（IDC）中的表达。
3. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. [J] . Yu KD, Wu LM, Liu GY, Annals of surgical oncology . 2011,第5期

机译：乳腺原位癌（DCIS），具有微浸润的DCIS和具有浸润成分的DCIS中乳腺癌亚型的不同分布。
4. Serum Biomarker Concentrations in Benign Breast Conditions and Ductal Carcinoma In Situ: Designing a Diagnostic Biomarker Panel That Can Distinguish Between Benign Conditions and Invasive Breast Cancer [C] . David E. Reese, Meredith C. Henderson, Susan Yeh, Molecular Medicine TRI-CON. . 2014

机译：血清生物标志物浓度在良性乳腺条件和导管癌原位：设计诊断生物标志物面板，可以区分良性条件和侵袭性乳腺癌
5. 14-3-3 zeta mediated epithelial -mesenchymal transition (EMT) contributes to ErbB2 overexpressing ductal carcinoma in situ (DCIS) progression into invasive breast cancer [D] . Lu, Jing 2008

机译：14-3-3 Zeta介导的上皮-间质转化（EMT）有助于ErbB2过表达导管原位癌（DCIS）演变为浸润性乳腺癌
6. Imaging features that distinguish pure ductal carcinoma in situ (DCIS) from DCIS with microinvasion [O] . Hongli Wang, Jinjiang Lin, Jianguo Lai, -1

机译：影像学特征可区分纯导管性原位癌（DCIS）和微浸润性DCIS
7. Image Guided Core Needle Biopsy (CNB) in Malignancy of The Breast—Part 2: Breast Ductal Malignancies other than Ductal Carcinoma In Situ (DCIS) and Invasive Ductal Carcinoma (IDC) [O] . Wilaiporn Bhothisuwan, Niramon Pantawanant, Naruporn Marukatat, 2021

机译：图像引导核心针活检（CNB）在乳房第2部分的恶性肿瘤中：乳腺导管恶性肿瘤原位（DCIS）和侵入性导管癌（IDC）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号